BMC, TIFR to look at second type of Covid-19 antibody
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
While the two serosurveys conducted in the city's three civic wards studied one type of antibody against the Covid-19-causing virus, researchers from BMC-run hospitals and the Tata Institute of Fundamental Research (TIFR) now plan to study the same samples for another type of antibody.

BMC-TIFR team looked at the nucleocapsid antibody as part of the surveys and now will also look at the longer-lasting RBD antibody.

Results of the serosurveys and the study will then be amalgamated to understand the "immune response" against the Covid-19 pandemic, said Dr Jayanthi Shastri, who heads the BMC-run Molecular Diagnostic Laboratory at Kasturba Hospital, Chinchpokli.

"Various antibodies develop and decay at different stages. The sero surveys we did in Mumbai looked at the nucleocapsid antibody as it develops first," said Dr Shastri. This antibody has a half-life of 70 days before it starts decaying.

Dr Ullas Kolthur, the other principal investigator from TIFR, said they will use some of the samples from the first and second serosurveys to look for the RBD antibody.

BMC's additional municipal commissioner Suresh Kakani had told TOI that the second survey had registered a drop in the levels of antibodies in the community in sync with a fall in the infection rate.

Source: https://health.economictimes.indiatimes.com/news/diagnostics/bmc-tifr-to-look-at-second-type-of-covid-19-antibody/78456071
A●●●n M●●●●a and 1 others like this
Like
Comment
Share